Get the Stockscreener App
72.66
0.22%
-0.16
Halozyme Therapeutics Inc stock is traded at $72.66, with a volume of 1.30M.
It is down -0.22% in the last 24 hours and up +9.84% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$72.82
Open:
$72.82
24h Volume:
1.30M
Relative Volume:
0.59
Market Cap:
$8.54B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
24.06
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+3.43%
1M Performance:
+9.84%
6M Performance:
+33.22%
1Y Performance:
+52.04%
1-Day Range:
$72.17
$74.25
1-Week Range:
$68.09
$74.25
52-Week Range:
$46.26
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
72.66 | 8.56B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here’s Why - Yahoo Finance
US Stocks Recap: Why Halozyme Therapeutics Inc. stock could see breakout soon2025 Sector Review & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Take Profit: Is Halozyme Therapeutics Inc. stock positioned for digital transformationWeekly Trend Report & Smart Investment Allocation Tips - BỘ NỘI VỤ
United StatesCahill Represents Lead Arrangers In Halozyme Therapeutics’ $750 Million Credit Facility - Mondaq
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - PR Newswire
Halozyme Therapeutics announces CFO transition agreement with Nicole LaBrosse By Investing.com - Investing.com Nigeria
Halozyme Announces CFO Transition Plan - TipRanks
Halozyme Therapeutics announces CFO transition agreement with Nicole LaBrosse - Investing.com
[8-K] HALOZYME THERAPEUTICS, INC. Reports Material Event | HALO SEC FilingForm 8-K - Stock Titan
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - MSN
Halozyme Acquires Drug Delivery Company Elektrofi - CHEManager
Quick ratio of Halozyme Therapeutics, Inc. – HAM:RV7 - TradingView
Is Halozyme Therapeutics Inc. (RV7) stock good for long term investingJuly 2025 PreEarnings & Precise Buy Zone Identification - newser.com
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects - Yahoo Finance
Is Halozyme Therapeutics Inc. (RV7) stock nearing a technical breakoutJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Using Python tools to backtest Halozyme Therapeutics Inc. strategies2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Why Halozyme Therapeutics Inc. stock is in analyst buy zone - newser.com
What Recent Analyst Upgrades and Partnerships Mean for Halozyme’s Evolving Story and Valuation - Yahoo Finance
Does the Latest Halozyme Partnership Signal Further Upside for the Stock in 2025? - Yahoo Finance
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
How strong dollar benefits Halozyme Therapeutics Inc. (RV7) stock2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Will Halozyme Therapeutics Inc. stock see PE expansionJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Goldman Sachs Maintains Halozyme Therapeutics (HALO) Neutral Recommendation - MSN
Halozyme Therapeutics expands portfolio with Elektrofi acquisition - Traders Union
How Halozyme Therapeutics Inc. (RV7) stock performs in volatility spikesWeekly Trade Review & Detailed Earnings Play Alerts - newser.com
[S-8] HALOZYME THERAPEUTICS, INC. Employee Benefit Plan Registration | HALO SEC FilingForm S-8 - Stock Titan
What drives Halozyme Therapeutics Inc stock priceVolume Profile Analysis & High Return Capital Gain - earlytimes.in
Goldman Sachs Raises Price Target for Halozyme Therapeutics (HAL - GuruFocus
Halozyme Therapeutics Acquires Elektrofi for $750M - Contract Pharma
Halozyme Therapeutics Completes Elektrofi Acquisition - MarketScreener
Halozyme completes acquisition of Elektrofi for $750 million By Investing.com - Investing.com Nigeria
Halozyme completes acquisition of Elektrofi for $750 million - Investing.com
Halozyme completes acquisition of Elektrofi, expanding breadth of offerings in drug delivery - MarketScreener
Halozyme (NASDAQ: HALO) buys Elektrofi for $750M, targeting Hypercon royalties by 2030 - Stock Titan
Halozyme Therapeutics, Inc. completed the acquisition of Elektrofi, Inc. - MarketScreener
Merus and Halozyme partner on subcutaneous cancer drug delivery By Investing.com - Investing.com Nigeria
Halozyme stock price target raised to $56 from $54 at Goldman Sachs - Investing.com
Merus N.V. and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - MarketScreener
Merus, Halozyme Partner to Develop Subcutaneous Formulation of Petosemtamab - Contract Pharma
Merus and Halozyme link up on petosemtamab development - The Pharma Letter
Merus Licenses ENHANZE Drug Delivery Technology Of Halozyme Therapeutics - Nasdaq
Halozyme (HALO) Enters Collaboration Agreement with Merus - GuruFocus
Merus and Halozyme enter global collaboration and license agreement to develop subcutaneous formulation of Petosemtamab - MarketScreener
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - Merus
Merus and Halozyme partner on subcutaneous cancer drug delivery - Investing.com
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab – Company AnnouncementFT.com - Financial Times
Merus (MRUS) and Halozyme (HALO) license ENHANZE to develop subcutaneous petosemtamab - Stock Titan
Will Halozyme Therapeutics Inc. price bounce be sustainablePortfolio Performance Summary & Community Driven Trade Alerts - newser.com
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Sale |
70.55 |
20,000 |
1,410,990 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Sale |
69.13 |
20,000 |
1,382,600 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Sale |
68.72 |
20,000 |
1,374,339 |
733,719 |
| Connaughton Bernadette | Director |
Nov 10 '25 |
Sale |
68.48 |
2,000 |
136,960 |
42,952 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):